More Scientific Evidence that the Anti-CD20 Chemo Drug Treats LYMErix-Disease

[Kathleen]

To: kathleen...@hhs.gov, francis...@nih.hhs.gov,
margaret...@fda.hhs.gov, dwh...@forbes.com,
ca...@drcarolgoodheart.com, lPick...@cdc.gov, Durlan...@yale.edu,
Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, margaret...@hhs.fds.gov,
emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@ct.gov, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@ct.gov, kur...@washpost.com, georg...@washpost.com,
p...@allegorypress.com, commissi...@po.state.ct.us,
brans...@comcast.net, vts...@comcast.net, o...@po.state.ct.us,
freet...@charter.net, scott....@po.state.ct.us,
govern...@po.state.ct.us, attorney...@ct.gov,
randall...@usdoj.gov, Robert....@yale.edu, editor@greenwich-
post.com, harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, bmi...@newstimes.com, tr...@hotmail.com,
rast...@aol.com, billc...@gmail.com, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com

Subject: More Scientific Evidence that the Anti-CD20 Chemo Drug Treats
LYMErix-Disease.

Date: Oct 25, 2011 4:39 PM

Scientific Breakthru Department:

http://www.actionlyme.org

=====================

Rituximab Clinical Trial Q&A, Developed by the ME Association
http://www.prohealth.com/library/showarticle.cfm?libid=16596

Follow up:

More proof that LYMErix caused the disease IDSA coined "the New Great
Imitator" (OspA promotes IL-10, which suppresses CD4+ function, which
controls EBV proliferation):

1) PubMed on EBV and CD20, demonstrating that Rituximab is an anti-
EBV, or Anti-CFIDS, or Anti-MS, or Anti-Lupus, or Anti-Chronic Lyme
drug:
http://www.ncbi.nlm.nih.gov/pubmed?term=EBV%5BAll+Fields%5D+AND+CD20%5BAll+Fields%5D&cmd=DetailsSearch

2) CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B cell
proliferation... [J Virol. 2001] - PubMed - NCBI
http://www.ncbi.nlm.nih.gov/pubmed/11264363
"Thus, unlike the killing of EBV-infected lymphoblastoid cell lines,
in which CD8+ cytolytic T cells play an essential role, prevention of
early-phase EBV-induced B-cell proliferation requires CD4+ effector T
cells."

3) Suppressed induction of mycobacterial antigen-specific Th1 CD4+
cells... [Int Immunol. 2010] - PubMed - NCBI
http://www.ncbi.nlm.nih.gov/pubmed/20167585
"Our data suggest that induction of anti-mycobacterial CD4(+) T(h)1
cells is suppressed in the mycobacteria-infected lung partially by
IL-10 [immunosuppressive cytokine elicited/promoted by OspA]."

4) and Allen Steere with his head up his ass, once again:
T helper 1 response is dominant and localized to the synovial fluid in
patients with Lyme arthritis.
http://www.ncbi.nlm.nih.gov/pubmed/9551943


And this is in addition to the other evidence that we have of Chronic
Epstein-Borreliosis (also caused by OspA injection):
http://www.actionlyme.org/101016.htm



5) Toll-like receptor agonists synergistically increase proliferation
and activation of B cells by epstein-barr virus.
http://www.ncbi.nlm.nih.gov/pubmed/20089650

6) Epstein-Barr virus induces MCP-1 secretion by human monocytes via
TLR2.
http://www.ncbi.nlm.nih.gov/pubmed/17522215
"Ligands for TLR2 or TLR7/8 or whole bacteria had a weaker but still
superadditive effect on B-cell transformation"

7) Interaction of Borrelia burgdorferi sensu lato with Epstein-Barr
virus in lymphoblastoid cells.
http://www.ncbi.nlm.nih.gov/pubmed/12630667

This is a mechanism that we did not know about before: IL-10 reducing
the number of CD4+ cells, which are required to keep EBV proliferation
under control.



1110125, 4PM, KMDickson once again, on what happens when you're not a
self-centered psychiatric pervert.


KMDickson